Search Results - ronnie+mease

6 Results

Sort By:

Long-Circulating PSMA-Targeted Phototheranostic Agent

Unmet NeedProstate cancer is the leading cancer in the U.S. population and the second leading cause of cancer death in men. A promising precision cancer treatment known as photodynamic therapy (PDT) offers a way to selectively target prostate cancer cells for destruction. Prostate PDT uses a ligand to attach a light-sensitizing agent known as porphyrin...

Published: 9/26/2024 | Inventor(s): Martin Pomper, Ronnie Mease, Ying Chen, Sangeeta Ray, Juan Chen, Marta Overchuk, Gang Zheng, Kara Harmatys

Keywords(s): Cancers, Disease Indication, Imaging and Sensing Systems, In Vivo Medical Imaging, Prostate Cancer, Target, Therapeutic Matter, Therapeutics

Category(s): Clinical and Disease Specializations > Oncology > Prostate Cancer, Clinical and Disease Specializations > Men's Health, Technology Classifications > Medical Devices > Imaging, Technology Classifications > Therapeutic Modalities > Targets

Competitive PSMA Binding Agents for Reduction of Non-target Organ Uptake of Radiolabeled PSMA Inhibitors for PSMA Positive Tumor Imaging and Radiopharmaceutical Therapy

Unmet NeedProstate cancer is the second leading cause of cancer related death in American men and it is estimated that approximately 164,690 new cases will be diagnosed in 2018. Elevated prostate-specific membrane antigen (PSMA) serves as a biomarker for prostate cancer and as well as primary clear cell renal carcinoma (ccRCC). However, PSMA is also...

Published: 9/26/2024 | Inventor(s): Martin Pomper, Ronnie Mease, Sangeeta Ray, Il Minn

Keywords(s): Cancers, Combination, Disease Indication, Imaging Agent, Imaging and Sensing Systems, In Vivo Medical Imaging, Prostate Cancer, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

A Preclinical Comparative Study of 68Ga-Labeled DOTA, NOTA and HBED-CC Chelated PSMA-targeted Radiotracers

Prostate cancer is the leading cancer in the U.S. population and the second leading cause of cancer death in men. Therapy for locally advanced disease remains contentious and an increasing number of disparate options are available. We have been engaged in the development of new, high-sensitivity, low molecular weight imaging agents for prostate cancer...

Published: 9/26/2024 | Inventor(s): Martin Pomper, Sangeeta Ray, Ronnie Mease

Keywords(s): Cancers, Disease Indication, Imaging Agent, Imaging and Sensing Systems, In Vivo Medical Imaging, Prostate Cancer

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Men's Health, Clinical and Disease Specializations > Oncology > Prostate Cancer, Technology Classifications > Medical Devices > Imaging, Technology Classifications > Medical Devices, Clinical and Disease Specializations > Oncology, Technology Classifications > Research Tools > Imaging

Radiolabeled Triazole Conjugated Ureas (YC-88)

Prostate-specific membrane antigen (PSMA) is a type II integral membrane protein expressed on the surface of prostate tumors, particularly in castrate-resistant, advanced and metastatic disease. PSMA is also expressed in neovascular endothelium of most solid tumors, such as lung, colon, pancreatic, renal carcinoma and skin melanoma, but not in normal...

Published: 9/26/2024 | Inventor(s): Martin Pomper, Ronnie Mease, Ying Chen, Sangeeta Ray, Xing Yang

Keywords(s): Antagonists/Inhibitors, Cancers, Discovery/Research Tools, Disease Indication, Imaging Agent, Imaging and Sensing Systems, In Vivo Medical Imaging, Labels/Markers, Novel, Predicted Novelty, Research Reagent, Single, Small Molecules, Targeted Therapy, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Research Tools, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Diagnostics, Technology Classifications > Therapeutic Modalities, Technology Classifications > Diagnostics > Diagnostic Imaging

New Scaffolds and Multifunctional Intermediates for Imaging PSMA

The prostate-specific membrane antigen (PSMA) is increasingly recognized as an important target for cancer imaging and therapy. Current PSMA inhibitors based on a urea scaffold have shown good results for imaging with positron emission tomography (PET) and single photon emission computed tomography (SPECT) in human subjects. The urea scaffold has...

Published: 9/26/2024 | Inventor(s): Martin Pomper, Ying Chen, Sangeeta Ray, Ronnie Mease, Xing Yang, Georgio Attardo

Keywords(s): Cancers, Disease Indication, Imaging Agent, Imaging and Sensing Systems, Imaging Modality, In Vivo Medical Imaging, Positron Emission Tomography (PET), Prostate Cancer

Prostate-specific Membrane Antigen-targeted Photosensitizers for Photodynamic Therapy

Targeted photodynamic therapy for prostate and solid-tumorsJHU REF: C12525Invention novelty: This invention is a novel drug composition that can target prostate tumors in vivo for use in photodynamic therapy (PDT).Value Proposition:Currently, prostate cancer treatment often requires invasive surgery or treatment with drugs that may cause adverse side-effects....

Published: 9/26/2024 | Inventor(s): Ying Chen, Ronnie Mease, Martin Pomper

Keywords(s): Cancers, Disease Indication, Drug Delivery Vehicle, Imaging Agent, Imaging and Sensing Systems, In Vivo Medical Imaging, Novel, Predicted Novelty, Prostate Cancer, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Men's Health, Clinical and Disease Specializations > Oncology > Prostate Cancer, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities